ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Safely Reduce a Common Cause of Stomach Distress

 
Print Page
Email Article

Hemispherx Biopharma to Present New Data on Activity of Ampligen in Treating Chronic Fatigue Syndrome at Annual CFS Conference

  [ 104 votes ]   [ Discuss This Article ]
www.ProHealth.com • September 27, 2004


PHILADELPHIA--(BUSINESS WIRE)--Sept. 27, 2004-- Compares Activity of Ampligen(R) to Alzheimer Drug for Potential Treatment

Hemispherx Biopharma, Inc. (AMEX:HEB), a leading developer of immune based therapies to treat Chronic Fatigue Syndrome (CFS) and HIV/AIDS, announced today that it will present new data on controlled testing of Ampligen(R) at the upcoming International CFS meeting in Madison, Wisconsin on October 9, 2004. Hemispherx's drug, Ampligen(R), an experimental immunotherapeutic, demonstrated medically and statistically significant increase in the primary endpoint, exercise treadmill duration, compared to placebo after a 40 week period. The Company, at the Conference, will present additional data on its clinical activities.

A number of drugs have been tested, and reported upon, in the treatment of CFS. In the current issue of JAMA, Dr. C. V. Russell Blacker from Exeter, UK and colleagues assessed the outcome of 434 CFS patients who were treated with one of four doses of Reminyl, which is manufactured by Shire Phamaceuticals or with an inactive "placebo". After 16 weeks of treatment, there were no statistically significant differences between any Reminyl or placebo groups in clinical condition on the primary end point, Clinician Global Impression Scale, or for any of the secondary end points. Exploratory regression analysis failed to detect any consistent prognostic factor that might have influenced the primary or secondary outcome measures, as reported in the September 8, 2004 Journal of the American Medical Association. "We remain encouraged that our protocol is the only one that addresses the large unmet medical need of patients with CFS," said William Carter, M.D. "We look forward to initiating steps designed to bring this product to market as rapidly as possible."

About Chronic Fatigue Syndrome CFS is defined by various governmental agencies worldwide as a serious debilitating disease in which patients suffer from complex symptoms, primary profound fatigue which severely limits daily activities. The CDC has added CFS to its top priority list of emerging infectious diseases. CFS is a worldwide disease estimated to affect over 500,000 people in the U.S. and a similar number in Europe and Asia.

About Ampligen(R) Ampligen(R) is an experimental, double stranded RNA drug acting potentially as an immunomodulator and antiviral. Based on in vitro studies, Ampligen is believed to modulate the immune system as well as inhibit viruses directly. The experimental product is currently in a Phase III clinical trial for the potential treatment of Chronic Fatigue Syndrome (CFS) and in two Phase IIb clinical trials for the potential treatment of HIV/AIDS. The FDA has already granted Ampligen Treatment IND Status and Orphan Drug Status. Treatment IND status was granted after an earlier reported study of 24 weeks duration consisting of 92 patients with severe CFS randomized to receive either Ampligen or Placebo. Only governmental regulatory agencies can make a definitive determination that the presumed efficacy/safety ratio of any new drug supports its commercial introduction for any disorder, including potential CFS treatment.

About Hemispherx Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has over 200 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition; changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indication.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg Optimized Curcumin Longvida®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients
Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera
The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away
Sleep Like a Baby in Nature's Cradle Sleep Like a Baby in Nature's Cradle
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map